arrow
K

Kakuhiro Yamaguchi

Department of Respiratory Medicine
H指数:18
被引数:1,147

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs

更正:血清总VEGF-A和VEGF-A亚型在EGFR突变型晚期非小细胞肺癌患者接受EGFR-TKIs治疗中的临床意义

2026-07-060
OAAI
Clinical implications of serum total VEGF-A and VEGF-A isoforms in patients with EGFR-mutated advanced non-small cell lung cancer treated with EGFR-TKIs

血清总VEGF-A和VEGF-A亚型在EGFR突变型晚期非小细胞肺癌经EGFR-TKIs治疗患者中的临床意义

2026-06-090
OAAI
Baseline Neutrophil-To-Lymphocyte Ratio as a Risk Stratification Marker for Severe Checkpoint Inhibitor Pneumonitis in Patients With Non-Small Cell Lung Cancer: A Two-Cohort Study With Retrospective Discovery and Prospective Validation

基线中性粒细胞与淋巴细胞比值作为非小细胞肺癌患者严重免疫检查点抑制剂肺炎风险分层标志物的两队列研究:回顾性发现与前瞻性验证

2026-06-040
OA
The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004)

HMGB1在重度检查点抑制剂肺炎风险评估中的临床潜力:一项前瞻性多中心研究(CS-Lung004)

2025-07-050
OA
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study

30天内出现皮肤疾病是接受尼妥珠单抗联合吉西他滨和顺铂治疗的肺鳞状细胞癌患者的有利预后因素:NINJA研究的亚组分析

2025-03-150
OA
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study

尼妥珠单抗联合顺铂和吉西他滨治疗在晚期肺鳞状细胞癌患者中诱导低镁血症的临床影响:NINJA研究的亚组分析

2025-02-140
OA
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
2023-12-014
OA